BOSTON, Oct. 29, 2026 /PRNewswire/ — CereVasc, Inc., a clinical-stage medical device company developing novel, minimally invasive treatments for neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) application to evaluate the eShunt System in patients with early symptomatic Alzheimer’s disease (AD).
AD is the most common cause of dementia, affecting an estimated 7.4 million Americans age 65 and older, as well as millions of family members and caregivers. Without medical breakthroughs that prevent, delay, or cure the disease, that number is projected to reach 13.8 million by 2060, underscoring the need for continued innovation.